These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 23140030)

  • 1. Prognostic factors and survival of borderline ovarian tumors in Rajavithi Hospital between 1979-2006 A.D.
    Sornsukolrat S; Tuipae S
    J Med Assoc Thai; 2012 Sep; 95(9):1141-8. PubMed ID: 23140030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
    Yang ZJ; Wei RJ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micropapillary pattern in serous borderline ovarian tumors: does it matter?
    Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
    Gynecol Oncol; 2011 Dec; 123(3):511-6. PubMed ID: 21917305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes.
    Tangjitgamol S; Hanprasertpong J; Manusirivithaya S; Wootipoom V; Thavaramara T; Buhachat R
    Acta Obstet Gynecol Scand; 2010; 89(2):182-9. PubMed ID: 19961281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence and prognostic factors in borderline ovarian tumors.
    Ayhan A; Guvendag Guven ES; Guven S; Kucukali T
    Gynecol Oncol; 2005 Sep; 98(3):439-45. PubMed ID: 16009407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy.
    Kapp KS; Kapp DS; Poschauko J; Stücklschweiger GF; Hackl A; Pickel H; Petru E; Winter R
    Gynecol Oncol; 1999 Sep; 74(3):400-7. PubMed ID: 10479500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre.
    Anfinan N; Sait K; Ghatage P; Nation J; Chu P
    Arch Gynecol Obstet; 2011 Sep; 284(3):731-5. PubMed ID: 20963432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of a sarcomatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/mullerian tumors: a clinicopathologic study of 47 cases.
    Kunkel J; Peng Y; Tao Y; Krigman H; Cao D
    Am J Surg Pathol; 2012 Jun; 36(6):831-7. PubMed ID: 22588065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
    Suh-Burgmann E
    Gynecol Oncol; 2006 Dec; 103(3):841-7. PubMed ID: 16793124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
    Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
    Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
    Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors predicting recurrence in borderline ovarian tumors.
    Wu TI; Lee CL; Wu MY; Hsueh S; Huang KG; Yeh CJ; Lai CH
    Gynecol Oncol; 2009 Aug; 114(2):237-41. PubMed ID: 19481786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.